Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Study identifier:D5660C00017

ClinicalTrials.gov identifier:NCT03394144

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD9150 monotherapy and AZD9150 in combination with durvalumab in Japanese patients with Advanced Solid Malignancies

Medical condition

Advanced solid malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD9150, Durvalumab

Sex

All

Actual Enrollment

11

Study type

Interventional

Age

20 Years - 120 Years

Date

Study Start Date: 30 Jan 2018
Primary Completion Date: 12 Apr 2019
Study Completion Date: 12 Apr 2019

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria